129 related articles for article (PubMed ID: 20425315)
21. Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways.
Edelmann J; Dokal AD; Vilventhraraja E; Holzmann K; Britton D; Klymenko T; Döhner H; Cragg M; Braun A; Cutillas P; Gribben JG
iScience; 2021 Feb; 24(2):102089. PubMed ID: 33615197
[TBL] [Abstract][Full Text] [Related]
22. Decrypting drug actions and protein modifications by dose- and time-resolved proteomics.
Zecha J; Bayer FP; Wiechmann S; Woortman J; Berner N; Müller J; Schneider A; Kramer K; Abril-Gil M; Hopf T; Reichart L; Chen L; Hansen FM; Lechner S; Samaras P; Eckert S; Lautenbacher L; Reinecke M; Hamood F; Prokofeva P; Vornholz L; Falcomatà C; Dorsch M; Schröder A; Venhuizen A; Wilhelm S; Médard G; Stoehr G; Ruland J; Grüner BM; Saur D; Buchner M; Ruprecht B; Hahne H; The M; Wilhelm M; Kuster B
Science; 2023 Apr; 380(6640):93-101. PubMed ID: 36926954
[TBL] [Abstract][Full Text] [Related]
23. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells.
Goyal Y; Busch GT; Pillai M; Li J; Boe RH; Grody EI; Chelvanambi M; Dardani IP; Emert B; Bodkin N; Braun J; Fingerman D; Kaur A; Jain N; Ravindran PT; Mellis IA; Kiani K; Alicea GM; Fane ME; Ahmed SS; Li H; Chen Y; Chai C; Kaster J; Witt RG; Lazcano R; Ingram DR; Johnson SB; Wani K; Dunagin MC; Lazar AJ; Weeraratna AT; Wargo JA; Herlyn M; Raj A
Nature; 2023 Aug; 620(7974):651-659. PubMed ID: 37468627
[TBL] [Abstract][Full Text] [Related]
24. Wound healing and aging.
Gerstein AD; Phillips TJ; Rogers GS; Gilchrest BA
Dermatol Clin; 1993 Oct; 11(4):749-57. PubMed ID: 8222358
[TBL] [Abstract][Full Text] [Related]
25. Hemoptysis Resolution with Rituximab in Behçet's Disease: A Case Report.
Jamaati H; Eskandari R; Sharif-Kashani B; Haghgoo R; Dastan F
Tanaffos; 2022 Mar; 21(3):401-404. PubMed ID: 37025315
[TBL] [Abstract][Full Text] [Related]
26. Targeting CD20: teaching an old dog new tricks.
Sharman JP
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):273-278. PubMed ID: 31808844
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
[TBL] [Abstract][Full Text] [Related]
28. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
29. What signals are generated by anti-CD20 antibody therapy?
Bonavida B
Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
[TBL] [Abstract][Full Text] [Related]
30. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
31. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
32. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
Jazirehi AR; Bonavida B
Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
[TBL] [Abstract][Full Text] [Related]
33. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
[TBL] [Abstract][Full Text] [Related]
34. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
Suzuki E; Umezawa K; Bonavida B
Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
[TBL] [Abstract][Full Text] [Related]
35. Prolonging remission with rituximab maintenance therapy.
Hainsworth JD
Semin Oncol; 2004 Feb; 31 Suppl 2():17-21. PubMed ID: 28140104
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
